1
Rusch Volker Dipl Biol Dr Rer, Reichhart Robert Dipl Chem, Zeppezauer Michael Prof Dr Rer, Jornvall Hans Prof Dr: Biologically active substance with hormonal characteristics, process for its preparation and use of histons for medicinal ends.. Rusch Volker, July 24, 1985: EP0149468-A2 (5 worldwide citation)

The invention relates to the use of pure histones H1, or the histone dimer H2A:H2B for therapeutic procedures. Instead of the pure histones active segments thereof with hormone or hormone like activity especially thymic hormone like activity can be used alone or in combination with the pure histones ...


2
Zeppezauer Michael, Reichhart Robert: Pure histone h1 for use in therapeutic procedures.. Symbiotec, October 17, 1990: EP0392315-A1 (5 worldwide citation)

The invention relates to the use of pure histones H1, or the histone dimer H2A:H2B for therapeutic procedures. Instead of the pure histones active segments thereof with hormone or hormone like activity especially thymic hormone like activity can be used alone or in combination with the pure histones ...


3
Class Reiner, Soslau Gerald, Zeppezauer Michael: Compositions and methods for preventing platenet aggegation. Philadelphia Health & Educatio, December 17, 2003: EP1370248-A1 (1 worldwide citation)

Compositions and methods for preventing platelet aggregation and treating cardiovascular disease via histone compounds are provided.


4
Zeppezauer Michael Prof Dr, Leinenbach Hans Peter Dr: Cytostatic or cytotoxic combination of active subtances for use in therapeutic procedures.. Symbiotec, July 31, 1991: EP0438756-A1 (1 worldwide citation)

The combination of agents according to the invention for use in therapeutic procedures, in particular for the treatment of cancers or autoimmune diseases, consists of at least one cytostatic (e.g. vincristine, methotrexate, cisplatin) as a first agent and of at least one histone and/or at least one ...


5
Zeppezauer Michael Prof Dr, Schoenberger Arno Dr, Cebecauer Ladislav Dr: Peptides for the preparation of means for diagnosis and therapy of systemic lupus.. Symbiotec, March 24, 1993: EP0532979-A2 (1 worldwide citation)

Peptides having antigenic or immunogenic determinants are proposed which are recognised by autoantibodies, in particular in body fluids of patients who suffer from systemic lupus erythematosus (SLE). The two peptides are preferably the C-terminus of H1 containing the sequence section 187 - 211 and t ...


6

7
Zeppezauer Michael, Schonberger Arno, Cebecauer Ladislav: Peptides entrant dans la fabrication de preparations utilisees pour le diagnostic et le traitement du lupus erythemateux aigu dissemine, Peptides for the production of preparations for the diagnosis and therapy of systemic lupus. Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der, OGILVY RENAULT SENCRLSRL, January 5, 1999: CA2078373

Peptides are proposed with antigenic or immunogenic determinants, which result from autoantibodies in the body fluids of patients, who are suffering from systemic lupus erythematosus (SLE). In the case of the peptides it is preferably a question of the C terminus of H1 with the sequence section 187 ...


8
Reichhart Robert, Jornvall Hans, Rusch Volker, Zeppezauer Michael: Substance biologiquement active ayant des proprietes hormonales, prodede de production et application dhistones a des fins medicales, Biologically active substance with hormonal properties, process for its production and application of histones for medical purposes. Volker Rusch, OGILVY RENAULT SENCRLSRL, March 14, 1989: CA1251134

ABSTRACT OF THE DISCLOSURE A biologically active substance with standardized effect isproposed, containing in a physiological medium at least onehistone, particularly an H2 histone or an active region of thishistone. The use of histones and/or histone segments forproducing such a preparation is also ...


9
Zeppezauer Michael, Leinenbach Hans Peter: Combinaison de substances presentant une activite cytostatique ou cytotoxique et utilisables dans le cadre dinterventions therapeutiques, Cytostatic or cytotoxic combination of active substances for use in therapeutic procedures. Zeppezauer Michael, Leinenbach Hans Peter, Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der, OGILVY RENAULT SENCRLSRL, January 21, 1997: CA2033249

According to this invention the combination of activesubstances for use in therapeutic procedures consists ofat least one cytostatic compound, e.g. vincristine,methotrexate, cisplatin as the first agent and at leastone histone and/or one active histone fragment withcytostatic or cytotoxic activity a ...


10
Zeppezauer Michael, Class Reiner: Use of histones for therapeutic purposes. Symbiotec Ges Fur Forschu, geqiang qinkai zong, April 30, 2008: CN200680015721

The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of thrombocytopenia.